CN104411684B - 苯氧基乙基哌啶化合物 - Google Patents

苯氧基乙基哌啶化合物 Download PDF

Info

Publication number
CN104411684B
CN104411684B CN201380034168.8A CN201380034168A CN104411684B CN 104411684 B CN104411684 B CN 104411684B CN 201380034168 A CN201380034168 A CN 201380034168A CN 104411684 B CN104411684 B CN 104411684B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
mmol
mixture
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380034168.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104411684A (zh
Inventor
M·A·席夫勒
J·S·约克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104411684A publication Critical patent/CN104411684A/zh
Application granted granted Critical
Publication of CN104411684B publication Critical patent/CN104411684B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380034168.8A 2012-06-29 2013-06-20 苯氧基乙基哌啶化合物 Active CN104411684B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US61/665,951 2012-06-29
US201361779099P 2013-03-13 2013-03-13
US61/779,099 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (2)

Publication Number Publication Date
CN104411684A CN104411684A (zh) 2015-03-11
CN104411684B true CN104411684B (zh) 2016-08-24

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380034168.8A Active CN104411684B (zh) 2012-06-29 2013-06-20 苯氧基乙基哌啶化合物

Country Status (42)

Country Link
US (2) US8962659B2 (OSRAM)
EP (1) EP2867207B1 (OSRAM)
JP (1) JP6127136B2 (OSRAM)
KR (1) KR101653476B1 (OSRAM)
CN (1) CN104411684B (OSRAM)
AP (1) AP2014008164A0 (OSRAM)
AR (1) AR091429A1 (OSRAM)
AU (1) AU2013280875B2 (OSRAM)
BR (1) BR112014031616B1 (OSRAM)
CA (1) CA2875569C (OSRAM)
CL (1) CL2014003535A1 (OSRAM)
CO (1) CO7151507A2 (OSRAM)
CR (1) CR20140553A (OSRAM)
CY (1) CY1119425T1 (OSRAM)
DK (1) DK2867207T3 (OSRAM)
DO (1) DOP2014000287A (OSRAM)
EA (1) EA024392B1 (OSRAM)
EC (1) ECSP14033267A (OSRAM)
ES (1) ES2644812T3 (OSRAM)
GT (1) GT201400288A (OSRAM)
HR (1) HRP20171515T1 (OSRAM)
HU (1) HUE034425T2 (OSRAM)
IL (1) IL236219A (OSRAM)
JO (1) JO3296B1 (OSRAM)
LT (1) LT2867207T (OSRAM)
MA (1) MA37686B1 (OSRAM)
ME (1) ME02840B (OSRAM)
MX (1) MX345324B (OSRAM)
MY (1) MY173878A (OSRAM)
NZ (1) NZ701933A (OSRAM)
PE (1) PE20150182A1 (OSRAM)
PH (1) PH12015500009B1 (OSRAM)
PL (1) PL2867207T3 (OSRAM)
PT (1) PT2867207T (OSRAM)
RS (1) RS56452B1 (OSRAM)
SG (1) SG11201408641UA (OSRAM)
SI (1) SI2867207T1 (OSRAM)
TN (1) TN2014000501A1 (OSRAM)
TW (1) TWI599561B (OSRAM)
UA (1) UA114325C2 (OSRAM)
WO (1) WO2014004229A1 (OSRAM)
ZA (1) ZA201408632B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
PL3083562T3 (pl) 2013-12-17 2018-02-28 Eli Lilly & Company Pochodne fenoksyetylowych cyklicznych amin i ich aktywność jako modulatorów receptora EP4
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
JP7488269B2 (ja) * 2019-01-22 2024-05-21 キーセラ・(スーチョウ)・ファーマシューティカルズ・カンパニー・リミテッド Pge2/ep4シグナル伝達を阻害する化合物、その製造方法及びその医薬における応用
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
CN1950333A (zh) * 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
CN1950334A (zh) * 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
CN102026961A (zh) * 2008-05-14 2011-04-20 安斯泰来制药株式会社 酰胺化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
MXPA05007341A (es) * 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
AU2007260529B2 (en) 2006-06-12 2012-04-19 Merck Canada Inc. Indoline amide derivatives as EP4 receptor ligands
EP2320906B1 (en) 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
CN102770159A (zh) 2010-02-22 2012-11-07 拉夸里亚创药株式会社 Ep-4受体拮抗剂在治疗il-23介导疾病中的用途
SMT201700008T1 (it) * 2010-09-21 2017-03-08 Eisai R&D Man Co Ltd Composizione farmaceutica
DK2729445T3 (en) * 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
US9120824B2 (en) * 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
CN1950333A (zh) * 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
CN1950334A (zh) * 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
CN102026961A (zh) * 2008-05-14 2011-04-20 安斯泰来制药株式会社 酰胺化合物

Also Published As

Publication number Publication date
TW201412717A (zh) 2014-04-01
IL236219A (en) 2017-12-31
CA2875569A1 (en) 2014-01-03
EP2867207A1 (en) 2015-05-06
CO7151507A2 (es) 2014-12-29
AR091429A1 (es) 2015-02-04
JO3296B1 (ar) 2018-09-16
DK2867207T3 (en) 2017-09-11
CA2875569C (en) 2016-04-19
CR20140553A (es) 2015-02-04
PH12015500009A1 (en) 2015-03-02
WO2014004229A1 (en) 2014-01-03
HRP20171515T1 (hr) 2017-11-17
HUE034425T2 (en) 2018-02-28
MA37686A1 (fr) 2016-09-30
ES2644812T3 (es) 2017-11-30
SG11201408641UA (en) 2015-01-29
MY173878A (en) 2020-02-26
PH12015500009B1 (en) 2020-10-09
BR112014031616B1 (pt) 2022-06-21
EP2867207B1 (en) 2017-08-09
ECSP14033267A (es) 2015-09-30
UA114325C2 (uk) 2017-05-25
PT2867207T (pt) 2017-11-01
JP2015522018A (ja) 2015-08-03
US8962659B2 (en) 2015-02-24
GT201400288A (es) 2015-08-27
AU2013280875A1 (en) 2014-12-04
US9402838B2 (en) 2016-08-02
TN2014000501A1 (en) 2016-03-30
EA201492255A1 (ru) 2015-03-31
LT2867207T (lt) 2017-10-10
CN104411684A (zh) 2015-03-11
ME02840B (me) 2018-01-20
MA37686B1 (fr) 2017-04-28
US20150126555A1 (en) 2015-05-07
HK1203937A1 (en) 2015-11-06
RS56452B1 (sr) 2018-01-31
MX2014015953A (es) 2015-07-17
EA024392B1 (ru) 2016-09-30
CL2014003535A1 (es) 2015-05-08
MX345324B (es) 2017-01-25
PE20150182A1 (es) 2015-02-13
DOP2014000287A (es) 2015-01-31
SI2867207T1 (sl) 2017-10-30
IL236219A0 (en) 2015-02-01
KR20150013893A (ko) 2015-02-05
PL2867207T3 (pl) 2018-01-31
TWI599561B (zh) 2017-09-21
ZA201408632B (en) 2017-06-28
AU2013280875B2 (en) 2015-09-24
KR101653476B1 (ko) 2016-09-01
US20140005226A1 (en) 2014-01-02
BR112014031616A2 (pt) 2017-06-27
AP2014008164A0 (en) 2014-12-31
CY1119425T1 (el) 2018-03-07
JP6127136B2 (ja) 2017-05-10
NZ701933A (en) 2017-01-27

Similar Documents

Publication Publication Date Title
CN104411684B (zh) 苯氧基乙基哌啶化合物
KR101634032B1 (ko) 디메틸-벤조산 화합물
CN105209438B (zh) 苯氧基乙基二氢‑1h‑异喹啉化合物
HK1203937B (en) Phenoxyethyl piperidine compounds
HK1203936B (en) Dimethyl-benzoic acid compounds useful for the treatment of inflammatory conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant